Endocrine Oncology Section, NIH/NCI/Surgery Branch, National Cancer Institute, NIH, Hatfield Clinical Research Center, Bethesda, Maryland 20892, USA.
Endocr Relat Cancer. 2012 Apr 10;19(2):157-66. doi: 10.1530/ERC-11-0308. Print 2012 Apr.
Currently, the diagnosis of malignant pheochromocytoma can only be made when there is clinical evidence of metastasis or extensive local invasion. Thus, there is a need for new diagnostic marker(s) to identify tumors with malignant potential. The purpose of this study was to identify microRNAs (miRNAs) that are differentially expressed between benign and malignant pheochromocytomas and assess their diagnostic accuracy. Toward this aim, we analyzed miRNA expression in benign and malignant pheochromocytoma tumor samples using whole genome microarray profiling. Microarray analysis identified eight miRNAs that were significantly differentially expressed between benign and malignant pheochromocytomas. We measured a subset of these miRNAs directly by RT-PCR and found that miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts. Area under the receiver operating curve (AUC) analysis indicated that miR-483-5p, miR-101, and miR-183 could be useful diagnostic markers for distinguishing malignant from benign pheochromocytomas. In addition, these miRNAs could be detected in pheochromocytoma patient serum. Overall our data suggest that misexpression of miR-483-5p, miR-101, and miR-183 is associated with malignant pheochromocytoma.
目前,只有当存在转移或广泛局部侵袭的临床证据时,才能诊断恶性嗜铬细胞瘤。因此,需要新的诊断标志物来识别具有恶性潜能的肿瘤。本研究的目的是鉴定良性和恶性嗜铬细胞瘤之间差异表达的 microRNAs(miRNAs),并评估其诊断准确性。为此,我们使用全基因组 microarray 分析分析了良性和恶性嗜铬细胞瘤肿瘤样本中的 miRNA 表达。微阵列分析鉴定了在良性和恶性嗜铬细胞瘤之间存在显著差异表达的 8 个 miRNAs。我们通过 RT-PCR 直接测量了这些 miRNAs 的一部分,发现 miR-483-5p、miR-183 和 miR-101 在恶性肿瘤中的表达明显高于良性肿瘤。受试者工作特征曲线(AUC)分析表明,miR-483-5p、miR-101 和 miR-183 可作为区分良恶性嗜铬细胞瘤的有用诊断标志物。此外,这些 miRNAs 可以在嗜铬细胞瘤患者的血清中检测到。总体而言,我们的数据表明 miR-483-5p、miR-101 和 miR-183 的表达失调与恶性嗜铬细胞瘤有关。